Medpace/$MEDP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Medpace
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Ticker
$MEDP
Sector
Primary listing
Industry
Life Sciences Tools and Services
Headquarters
Employees
6,000
Website
Medpace Metrics
BasicAdvanced
$13B
33.67
$13.46
1.47
-
Price and volume
Market cap
$13B
Beta
1.47
52-week high
$501.30
52-week low
$250.05
Average daily volume
649K
Financial strength
Current ratio
0.427
Quick ratio
0.348
Long term debt to equity
72.495
Total debt to equity
98.535
Profitability
EBITDA (TTM)
506.477
Gross margin (TTM)
68.51%
Net profit margin (TTM)
18.74%
Operating margin (TTM)
21.40%
Effective tax rate (TTM)
15.56%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
17.09%
Return on equity (TTM)
89.38%
Valuation
Price to earnings (TTM)
33.666
Price to revenue (TTM)
6.139
Price to book
73.65
Price to tangible book (TTM)
-24.23
Price to free cash flow (TTM)
23.631
Free cash flow yield (TTM)
4.23%
Free cash flow per share (TTM)
19.172
Growth
Revenue change (TTM)
9.94%
Earnings per share change (TTM)
26.42%
3-year revenue growth (CAGR)
20.16%
3-year earnings per share growth (CAGR)
32.76%
What the Analysts think about Medpace
Analyst ratings (Buy, Hold, Sell) for Medpace stock.
Bulls say / Bears say
Medpace reported a 7.7% increase in Q4 2024 revenue to $536.6 million, indicating strong financial performance. (Medpace Holdings, Inc.)
The company achieved a 49.4% surge in Q4 2024 net income to $117.0 million, reflecting improved profitability. (GuruFocus)
Medpace expanded its share repurchase program by $600 million, demonstrating confidence in its financial health and commitment to shareholder value. (GuruFocus)
Ongoing securities law investigations could lead to legal and financial repercussions, potentially affecting shareholder value. (Monexa)
In Q1 2025, Medpace reported a net book-to-bill ratio of 0.90, indicating a decline in net new business awards and potential future revenue challenges. (GuruFocus)
The company's stock is currently rated as a 'Hold,' suggesting limited immediate upside potential. (GuruFocus)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Medpace Financial Performance
Revenues and expenses
Medpace Earnings Performance
Company profitability
Medpace News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Medpace stock?
Medpace (MEDP) has a market cap of $13B as of July 29, 2025.
What is the P/E ratio for Medpace stock?
The price to earnings (P/E) ratio for Medpace (MEDP) stock is 33.67 as of July 29, 2025.
Does Medpace stock pay dividends?
No, Medpace (MEDP) stock does not pay dividends to its shareholders as of July 29, 2025.
When is the next Medpace dividend payment date?
Medpace (MEDP) stock does not pay dividends to its shareholders.
What is the beta indicator for Medpace?
Medpace (MEDP) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.